Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;10(Suppl 33):S3837-S3839.
doi: 10.21037/jtd.2018.09.52.

Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

John A Green  1
Affiliations
Editorial

Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

John A Green. J Thorac Dis. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Comment on

  • Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Clinical Trial.

References

    1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-11. - PMC - PubMed
    1. Greenhalgh J, Dwan K, Boland A, et al. First line treatment of epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2016;(5):CD010383. - PubMed
    1. Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89. 10.1016/S1470-2045(16)30033-X - DOI - PubMed
    1. Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther 2017;10:2473-82. 10.2147/OTT.S134382 - DOI - PMC - PubMed
    1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label Phase 3 trial. Lancet Oncol 2017;18:1454-66. 10.1016/S1470-2045(17)30608-3 - DOI - PubMed